June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success
May 27, 2025 How much does a Turkish passport cost?
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
Tilray (TLRY) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: June 22, 2025 (19:47)
Sector: HealthcareThe share price of Tilray, Inc. (TLRY) now
News Impact Analyzer
Full report
This Week
|
Na | Impact: Na | News: Na |
Previous Week
|
Bullish | Impact: 5 | News: 1 (1/0/0) |
Two Weeks Ago
|
Na | Impact: Na | News: Na |
Three Weeks Ago
|
Bearish | Impact: 5 | News: 1 |
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 1 (1/0/0) |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Neutral | Opinions: 1 |
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important TLRY news

Meta Eases Cannabis Content Restrictions on Facebook and Instagram


Red Flags for TLRY: Slipping Momentum and Negative EPS Revisions


Tilray Brands (TLRY) Faces Bearish Outlook Amid Decelerating Momentum

Historical and forecast chart of Tilray stock
The chart below shows the historical price of Tilray stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Tilray stock price can be found in the table below.
Long-term forecasts by years.
Tilray, Inc. Analysts predictions review

Tilray is navigating a mixed outlook. Bullish drivers include its diversified product offerings and international expansion, which may sustain long-term growth. Regulatory progress, especially potential U.S. legalization, remains a critical catalyst for upside, though its timing remains uncertain. However, bearish factors dominate in the near term, including dilution risks from equity issuance, weak financial performance relative to peers, and negative sentiment surrounding its reverse stock split. Macro pressures and regulatory delays further constrain growth prospects. Tilray's Q3 earnings outcome will be pivotal in determining whether strategic initiatives can restore confidence and mitigate these challenges.

Tilray Brands: Positioned for a Potential Upside Surge

The company's strategic focus on diversified product offerings, including beverages and personal care items, strengthens its resilience beyond core cannabis operations. According to the author, this diversification could mitigate risks and attract broader consumer categories, supporting revenue stability.
Market Potential and Operational Efficiency
Tilray's expansion into international markets taps into the growing global demand for cannabis products, which could drive significant top-line growth. Coupled with operational cost optimization strategies, the author emphasizes how these efforts may improve profit margins in the near term.
Regulatory developments in the cannabis industry, especially in the U.S., remain a critical driver of Tilray's stock performance. The author highlights that potential federal legalization could unlock massive market access, catalyzing investor interest and price momentum.

Tilray: Near-Term Risks Mount as Reverse Split Looms

Tilray (TLRY) is confronting significant headwinds that may challenge its stock performance in the near term. One of the primary concerns is the company's intention to execute a reverse stock split, which is often perceived negatively in equity markets. A reverse split can signal underlying financial distress, potentially deterring investor confidence and intensifying selling pressure.
Key Factors Impacting Tilray's Future
Another pivotal issue is the lackluster financial performance of the company relative to peers in the cannabis sector. Weak revenue growth and an inability to achieve consistent profitability undermine Tilray’s fundamentals, leaving its stock vulnerable to further declines amid broader industry challenges.
In addition, macroeconomic pressures and regulatory uncertainties continue to weigh on the cannabis sector as a whole. Prolonged delays in full-scale legalization in the U.S., a key growth market for Tilray, limit potential revenue upside and reinforce investor caution.
Lastly, dilution risk remains a pressing concern given Tilray’s historical reliance on equity offerings for capital raising. A reverse split could prompt additional equity issuance, further diluting existing shareholders and exacerbating downward pressure on the stock price.

Tilray Q3 Results: A Potential Pivot in Cannabis Sector Performance

Tilray's upcoming Q3 earnings report represents a critical juncture for the company, as its ability to demonstrate sustainable revenue growth remains pivotal amid challenging market dynamics. The author underscores that achieving profitability within its cannabis operations and associated businesses could significantly bolster investor confidence and improve its valuation trajectory.
The company's expansion efforts, particularly in Europe and its diversified product mix, have the potential to support long-term growth amid increasing global cannabis legalization trends. Array emphasizes that regulatory advancements could act as a tailwind, enabling Tilray to capitalize on wider market opportunities and consolidate its competitive position internationally.
Key Factors Driving Tilray's Performance
Operational efficiency and cost management were highlighted as primary areas of concern, given Tilray's need to navigate pricing pressures and competitive margins in a maturing cannabis market. This focus, if executed effectively, could lead to improved profitability metrics that strengthen shareholder value over the coming quarters.
Market sentiment will likely hinge on Tilray's ability to deliver on its strategic initiatives, including synergies from recent acquisitions. The author postulates that the firm’s ability to leverage these assets to drive both topline and bottom-line improvements may serve as a definitive litmus test for its mid-term growth prospects.
The rapid surge in short interest for Tilray (TLRY) signals heightened bearish sentiment among market participants. Elevated short interest often indicates investor skepticism over the company's near-term performance, signaling potential downside risk, but simultaneously setting the stage for volatility-driven short squeezes if upward catalysts emerge. The author's observation effectively underscores the dual nature of this metric as both a risk and an opportunity.
Key Drivers and Their Implications
Concerns over Tilray's financial fundamentals and broader sector-specific pressure could justify the increasing short interest. Cannabis companies, including Tilray, face challenges such as regulatory uncertainty, pricing pressure, and weaker-than-expected revenue growth, which weigh heavily on valuation prospects.
However, the author notes speculative dynamics, particularly fueled by retail investors, as a potential counterforce. A sudden price surge, whether due to positive sentiment or news-triggered momentum, could lead to a short squeeze, forcing bearish investors to unwind positions and drive stock price volatility.
Broader macroeconomic uncertainty and rising interest rates further pressure growth stocks like Tilray. This external backdrop compounds the company's internal struggles and dampens the appetite for high-risk investments in the near-term.
Tilray's improved balance sheet has become a pivotal factor in evaluating its financial health. The reduction of debt and enhanced liquidity position provide the company with greater operational flexibility, which is likely to bolster investor confidence and support future strategic initiatives.
Key Drivers of Tilray's Performance
The company's reasonable valuation relative to its peers positions it attractively within the cannabis industry. According to the author's analysis, this pricing advantage, combined with strengthening fundamentals, could generate renewed interest from value-focused investors in the near term.
However, sector-wide headwinds, including regulatory uncertainty and competitive pressures, continue to pose challenges. While Tilray appears to be navigating these headwinds effectively, they remain a critical variable that could impact investor sentiment and stock momentum.
Tilray's recent financial performance underscores critical concerns regarding its profitability trajectory. The company's widening net losses, coupled with declining revenue across certain key segments, raise pressing questions about its ability to achieve meaningful operational efficiency in the short term.
The author highlights that Tilray's strategic pivot toward diversification, particularly in the beverage alcohol and wellness sectors, has yet to yield significant value for shareholders. While these moves may hedge against weakness in the cannabis market, they introduce execution risks and dilute the company's focus on its core offerings, potentially limiting near-term upside.
Macro Headwinds and Competitive Pressures
Broader macroeconomic challenges, including inflationary pressures and shifting consumer spending patterns, have exacerbated Tilray's struggles. These external factors not only dampen discretionary spending on cannabis-related products but also intensify price competition within an already saturated market.
Furthermore, the absence of clear regulatory tailwinds in critical markets, such as the United States and Europe, remains a significant obstacle. In an industry heavily reliant on policy momentum, the lack of progress toward cannabis legalization undermines confidence in Tilray's growth narrative and restrains long-term valuation potential.
Tilray's performance continues to be overshadowed by operational inefficiencies and macroeconomic headwinds, as reflected in their near-term financial outlook. Key revenue growth remains constrained due to weak demand dynamics in core cannabis markets, exacerbated by oversupply pressures and regulatory hurdles, particularly in Canada. The author's analysis highlights that these industry-specific challenges are likely to cap revenue expansion efforts.
Factors Impacting Tilray's Stock Price
Profitability concerns loom large, with cost management efforts failing to meaningfully improve margins. This raises questions around the company's ability to scale efficiently, especially in light of increasing competition and stagnant pricing trends. According to the author, lack of cost discipline may weigh on investor sentiment in the near term.
While diversification into adjacent markets such as beverages and wellness products shows potential, the impact on revenue streams remains negligible. Tilray's mixed performance in non-core segments may not compensate for the broader declines in its cannabis division, and the author cautions against overestimating the short-term benefits of these initiatives.
Geographic expansion efforts, particularly in Europe, are progressing slowly, with regulatory approval timelines and market penetration challenges prolonging their revenue contribution. The author points out that these international endeavors may require significant capital, further pressuring profitability metrics.
Lastly, balance sheet concerns persist, with rising debt levels and constrained cash flows creating additional risk for shareholders. The author emphasizes that this financial strain could limit Tilray's ability to execute strategic investments, thereby weakening its competitive positioning.
The potential expansion of Tilray's (TLRY) market share within the US Delta-9 THC segment represents a pivotal driver for future growth. Amid loosening cannabis regulations and increasing consumer demand, this market offers a platform for substantial revenue growth, especially as state-level legalization accelerates. The author's note that Tilray is well-equipped to capitalize on this trend underscores management's strategic positioning within the fast-growing US cannabis market.
European Expansion: A Strategic Focus
The German medical cannabis market emerges as another significant growth lever for Tilray, given Europe's progressive stance on cannabis legalization. Germany's ongoing regulatory reforms and increasing adoption of medical cannabis present an opportunity for sustained demand, allowing Tilray to expand its footprint in the region. As highlighted by the author, this fosters potential cross-border synergies aligning with the company's broader international strategy.
Moreover, Tilray’s focus on operational efficiency and cost discipline remains crucial in weathering current macroeconomic conditions. The company's diversification into adjacencies such as beverages further buffers revenue volatility, illustrating an effort to stabilize financial performance. This adaptability, as suggested in the analysis, creates a longer-term margin expansion opportunity, though near-term results may fluctuate due to industry-wide pricing pressures.
The company’s strategic shift toward diversification, particularly its expansion within the beverage and wellness segments, could provide an essential growth lever. By leveraging its presence in these emerging markets, Tilray is positioning itself to reduce reliance on its core cannabis operations, which remain under pressure due to regulatory and market challenges.
Cost-cutting initiatives and operational efficiencies were highlighted as a significant area of focus. If executed successfully, these measures could improve the firm’s EBITDA margins and demonstrate prudent management amid broader industry headwinds.
Challenges in Core Operations vs. Emerging Tailwinds
However, the persistent oversupply within the cannabis market and sluggish demand growth may limit near-term stock appreciation. This structural issue poses a risk to profitability, as pricing pressures continue to weigh on the broader industry.
Finally, sentiment around federal cannabis legalization remains a pivotal factor for Tillray's stock performance. While optimism around regulatory reform has fueled speculative interest in the past, the lack of concrete legislative progress adds uncertainty, making this a longer-term catalyst rather than a short-term driver of stock price.
Comprehensive Analysis of Tilray (TLRY) Stock Market Performance
Our multifaceted analysis of Tilray's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Tilray stock?
- When should I record a loss on Tilray stock?
- What are analysts' forecasts for Tilray stock?
- What is the future of Tilray stock?
We forecast Tilray stock performance using neural networks based on historical data on Tilray stocks.
Unpacking Tilray Stocks: A Glimpse into the Future of Cannabis and Beverage Shares
In the ever-volatile world of the stock market, predicting the future direction of any stock, including Tilray Brands, Inc. (NASDAQ:TLRY), presents a spectrum of uncertainties. With TLRY’s recent financial disclosures and strategic shifts, investors find themselves at a crossroads, attempting to discern the potential pathways for TLRY stock prices and pondering the lingering question: is TLRY stock a buy?
Complex Dynamics Influencing TLRY Stock Predictions
A dive into Tilray’s recent financial quarter reveals a narrative of growth driven predominantly through acquisitions rather than organic expansion, notably within the cannabis domain. The firm’s pivot towards the beverage sector, marked by acquiring craft beer brands from Anheuser-Busch, reflects a strategic realignment that echoes throughout TLRY’s financial performance and, by extension, its stock valuation. This shift has sparked questions regarding the TLRY stock forecast, as investors wonder whether these acquisitions can morph into long-term gains.
TLRY’s Q2 reporting season shed light on a 34% year-over-year revenue increase, totaling $194 million, a figure slightly shy of analyst estimates. Despite this growth, TLRY’s struggle with cash burn, debt accumulation, and the specter of shareholder dilution looms large, influencing the TLRY stock prediction dialogues.
Especially pivotal to TLRY stock price prediction will be the unfolding landscape of U.S. federal cannabis legalization and potential major equity raises. These events bear the weight to either significantly propel the company forward or place further strains on its financial structure.
Predicting the trajectory of TLRY stock rates demands a nuanced understanding of both its evolving business model and broader market dynamics. While the recent focus on the beverage sector and cannabis revenue gains paint a mixed picture, the underlying challenges of debt management and market expansion remain key. As a result, whether investors will profit from their decisions to buy or sell TLRY stock depends largely on these upcoming events, making TLRY stock price predictions a difficult task due to the complexity and unknowns involved.
Tilray, a trailblazer in the cannabis industry, has its primary hub nestled in Nanaimo, British Columbia, Canada. This site isn’t just their headquarters; it’s also where they craft their products. Back in 2018, they proudly harvested a bountiful crop of medical cannabis at their facility in Portugal.
Their research and development haven in Nanaimo spreads across a whopping 18,300 square meters. The year 2018 was a banner year for them sales-wise, with the amount of product sold skyrocketing to 6,478 kilograms – more than double the previous year’s tally of 3,024 kilograms. It was clear that Tilray was on an impressive upward trajectory.
Tilray, Inc. News influencing stock rates

As of now, Panda has combed through 2 news items directly related to TLRY from the last 30 days. Out of these, 1 clearly showcase a bullish trend, while 1 display bearish tendencies, and 0 events are neutral.
The strength of the bearish trend is dominating bullish sentiments by 1.13 times, indicating that the current news landscape is negatively impacting the company's stock prices in the foreseeable future.
The news analyzed fell within the period from May 29, 2025, to Jun 14, 2025.
Top Cannabis Stocks: Experts' Picks for the Moment


DEA’s Marijuana Reclassification: A Game-Changer for Cannabis Stocks?


Tilray Medical Debuts Sugar-Free Cannabis Edibles in Australia


Tilray Brands Considers 1-to-20 Reverse Stock Split Amid Challenges


Tilray's Troubled Future: High Risk Ahead!


Tilray Aims High with $900M Revenue Projection by 2025 Amid Strategic Expansion


4 Stocks Poised for Market Attention: WBA, TLRY, MRVL, LLY


Tilray Misses Revenue Forecasts for Third Straight Quarter, Shares Dip


Tilray Stock at Risk: Negative EPS Revisions Signal Trouble


Tilray Stock Faces Strong Headwinds: Sell Signal Triggered


Tilray daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun 24 | 0.35 | 0.34 | 0.36 | 4.85 |
Jun 25 | 0.34 | 0.32 | 0.35 | 8.23 |
Jun 26 | 0.34 | 0.33 | 0.35 | 4.95 |
Jun 27 | 0.33 | 0.31 | 0.34 | 7.69 |
Jun 28 | 0.32 | 0.31 | 0.33 | 4.91 |
Jun 29 | 0.32 | 0.31 | 0.33 | 6.86 |
Jun 30 | 0.33 | 0.32 | 0.34 | 6.44 |
Jul 01 | 0.33 | 0.32 | 0.34 | 6.58 |
Jul 02 | 0.35 | 0.33 | 0.36 | 6.88 |
Jul 03 | 0.33 | 0.32 | 0.35 | 9.92 |
Jul 04 | 0.34 | 0.33 | 0.35 | 7.52 |
Jul 05 | 0.34 | 0.33 | 0.35 | 5.53 |
Jul 06 | 0.35 | 0.34 | 0.36 | 8.11 |
Jul 07 | 0.37 | 0.36 | 0.39 | 8.75 |
Jul 08 | 0.38 | 0.36 | 0.39 | 8.00 |
Jul 09 | 0.38 | 0.37 | 0.40 | 8.37 |
Jul 10 | 0.38 | 0.37 | 0.39 | 5.54 |
Jul 11 | 0.36 | 0.35 | 0.38 | 9.91 |
Jul 12 | 0.36 | 0.36 | 0.38 | 6.55 |
Jul 13 | 0.37 | 0.36 | 0.39 | 7.30 |
Jul 14 | 0.38 | 0.37 | 0.38 | 3.48 |
Jul 15 | 0.35 | 0.34 | 0.36 | 5.76 |
Jul 16 | 0.37 | 0.36 | 0.39 | 9.95 |
Jul 17 | 0.38 | 0.37 | 0.39 | 5.97 |
Jul 18 | 0.39 | 0.38 | 0.40 | 7.08 |
Jul 19 | 0.41 | 0.39 | 0.42 | 6.08 |
Jul 20 | 0.39 | 0.39 | 0.42 | 8.04 |
Jul 21 | 0.38 | 0.37 | 0.39 | 5.20 |
Jul 22 | 0.38 | 0.36 | 0.39 | 9.97 |
Jul 23 | 0.39 | 0.38 | 0.39 | 5.14 |
Tilray Daily Price Targets
Tilray Stock Forecast 06-24-2025.
Forecast target price for 06-24-2025: $0.35.
Negative dynamics for Tilray shares will prevail with possible volatility of 4.627%.
Pessimistic target level: 0.34
Optimistic target level: 0.36
Tilray Stock Forecast 06-25-2025.
Forecast target price for 06-25-2025: $0.34.
Negative dynamics for Tilray shares will prevail with possible volatility of 7.605%.
Pessimistic target level: 0.32
Optimistic target level: 0.35
Tilray Stock Forecast 06-26-2025.
Forecast target price for 06-26-2025: $0.34.
Negative dynamics for Tilray shares will prevail with possible volatility of 4.718%.
Pessimistic target level: 0.33
Optimistic target level: 0.35
Tilray Stock Forecast 06-27-2025.
Forecast target price for 06-27-2025: $0.33.
Negative dynamics for Tilray shares will prevail with possible volatility of 7.145%.
Pessimistic target level: 0.31
Optimistic target level: 0.34
Tilray Stock Forecast 06-28-2025.
Forecast target price for 06-28-2025: $0.32.
Negative dynamics for Tilray shares will prevail with possible volatility of 4.681%.
Pessimistic target level: 0.31
Optimistic target level: 0.33
Tilray Stock Forecast 06-29-2025.
Forecast target price for 06-29-2025: $0.32.
Positive dynamics for Tilray shares will prevail with possible volatility of 6.416%.
Pessimistic target level: 0.31
Optimistic target level: 0.33
TLRY (TLRY) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun. | 0.42 | 0.32 | 0.49 | 33.56 |
Jul. | 0.40 | 0.31 | 0.45 | 30.60 |
Aug. | 0.42 | 0.37 | 0.49 | 25.04 |
Sep. | 0.32 | 0.25 | 0.37 | 32.00 |
Oct. | 0.33 | 0.30 | 0.39 | 23.51 |
Nov. | 0.34 | 0.31 | 0.38 | 18.93 |
Dec. | 0.42 | 0.32 | 0.47 | 32.86 |
Tilray forecast for this year
Tilray Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $0.415817. Pessimistic: $0.32. Optimistic: $0.49
Tilray Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $0.402095. Pessimistic: $0.31. Optimistic: $0.45
Tilray Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $0.423808. Pessimistic: $0.37. Optimistic: $0.49
Tilray Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $0.322094. Pessimistic: $0.25. Optimistic: $0.37
Tilray Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $0.33369. Pessimistic: $0.30. Optimistic: $0.39
Tilray Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $0.335692. Pessimistic: $0.31. Optimistic: $0.38
Tilray Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $0.416258. Pessimistic: $0.32. Optimistic: $0.47
Tilray (TLRY) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 0.45 | 0.35 | 0.56 | 36.65 |
Mar | 0.42 | 0.37 | 0.51 | 27.50 |
Mar | 0.35 | 0.33 | 0.42 | 19.93 |
Apr | 0.30 | 0.24 | 0.32 | 25.05 |
May | 0.27 | 0.23 | 0.32 | 29.75 |
Jun | 0.27 | 0.22 | 0.32 | 30.41 |
Jul | 0.31 | 0.25 | 0.35 | 28.35 |
Aug | 0.40 | 0.33 | 0.47 | 29.64 |
Sep | 0.42 | 0.33 | 0.46 | 26.90 |
Oct | 0.52 | 0.41 | 0.57 | 29.29 |
Nov | 0.63 | 0.50 | 0.78 | 35.08 |
Dec | 0.78 | 0.60 | 0.97 | 38.17 |
Tilray (TLRY) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 0.63 | 0.58 | 0.76 | 24.30 |
Mar | 0.46 | 0.41 | 0.57 | 29.27 |
Mar | 0.53 | 0.43 | 0.59 | 27.86 |
Apr | 0.52 | 0.47 | 0.59 | 19.23 |
May | 0.51 | 0.45 | 0.61 | 25.98 |
Jun | 0.52 | 0.41 | 0.62 | 34.73 |
Jul | 0.67 | 0.51 | 0.73 | 30.28 |
Aug | 0.80 | 0.65 | 0.93 | 30.39 |
Sep | 0.74 | 0.66 | 0.88 | 24.85 |
Oct | 0.83 | 0.64 | 0.89 | 28.19 |
Nov | 0.60 | 0.51 | 0.66 | 22.05 |
Dec | 0.44 | 0.34 | 0.48 | 28.51 |
Tilray information and performance
1100 MAUGHAN ROAD, NANAIMO, BC, CA
Market capitalization of the Tilray, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TLRY shares in the company outstanding by the market price of one share.
EBITDA of Tilray is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
FAQ (Frequently Asked Questions about Tilray Stock)
Should I Buy Tilray Shares in 2025 year?
Does Tilray pay dividends?
Which economic sector do Tilray's shares belong to?
Which other securities belong to the same sector as Tilray's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.